论文部分内容阅读
目的拟对卡泊芬净在器官移植术后患者深部真菌感染治疗过程中的安全性进行评价。方法采用病例对照研究方法,以应用氟康唑或两性霉素B治疗的患者为对照组,数据采用SPSS14.0处理。结果试验组和对照2组患者治疗前后ALT,对照2组患者治疗前后血BUN治疗前后的差异有统计学意义(P<0.05)。试验组和对照2组用药后血浆电解质水平有所变化(P<0.05)。对照1组用药前后他克莫司血药浓度有统计学意义。3组不良反应发生率分别为5.6%,5.6%和14.3%。结论卡泊芬净用于治疗移植术后患者深部真菌感染有较好的安全性。
Objective To evaluate the safety of caspofungin in the treatment of deep fungal infections in patients after organ transplantation. Methods A case-control study was conducted in patients treated with fluconazole or amphotericin B as control group. The data were analyzed by SPSS14.0. Results Before and after treatment, the difference between before and after treatment of ALT in control group and control group before and after treatment was statistically significant (P <0.05). The levels of plasma electrolytes changed in both experimental and control groups (P <0.05). Control group 1 before and after tacrolimus plasma concentration was statistically significant. Adverse reactions in the three groups were 5.6%, 5.6% and 14.3%, respectively. Conclusion Caspofungin for the treatment of patients with deep fungal infection after transplantation has better safety.